What is post-transplant lymphoproliferative disorder?

Occurs within a few months after BMT Highly associated with T-cell Depletion Product depletion techniques that preserve B-cells CD34+ selection CD3+ selection without CD19+ depletion Cord blood with ATG In vivo depletion (ATG, less with Alemtuzumab) Therapy that is highly T-cell suppressive ATG for resistant GVHD Treatment IS withdrawal, Rituximab, cyclophosphamide, EBV-targeted cytotoxic T-lymphocytes (CTLs)